Edwards Lifesciences' (EW) Board Approves New $250 Million Share Buyback Program
More News related to EW
- Edwards Lifesciences' New Transcatheter Heart Valve Data Demonstrate Positive Results
- Edwards Lifesciences to Present at the UBS Global Life Sciences Conference
- Edwards Lifesciences Presents New Transcatheter Heart Valve Data at EACTS
- Morgan Stanely Assumes Coverage on Edwards Lifesciences (EW) with an Equalweight
- Edwards Lifesciences (EW) Receives FDA Approval for PERIMOUNT Magna Mitral Heart Valve
More News related to Stock Buybacks
- Maxim Integrated (MXIM) Issues Mixed Guidance, Approves $750 Million Stock Buyback
- Analogic (ALOG) Announces $25M Buyback
- Sterling Construction (STRL) Authorizes $5M Buyback
- Avatar Holdings (AVTR) Amends Repurchase Plan
- Avatar (AVTR) Amends Securities Repurchases
Edwards Lifesciences Corporation (NYSE: EW) announced that its board of directors has authorized a new share repurchase program to acquire up to $250 million of the company's outstanding common shares. Edwards recently completed a $250 million share repurchase program that its board of directors approved in September 2007.
During the first half of 2008, Edwards repurchased a total of 4.6 million shares for approximately $235 million. As of June 30, 2008, the company had approximately 56.2 million shares of common stock outstanding.
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring.
Related Categories
Stock BuybacksStocks Mentioned
+6.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
